Ulrik Mouritzen - Concepedia

Author

Ulrik Mouritzen

Zealand Pharma (Denmark)ORCID

Also Known As

U Mouritzen, U. Mouritzen, ULRIK MOURITZEN, Ulrik Mouritzen

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Zealand Pharma (Denmark)Center for Clinical & Basic Research Novo Nordisk (Denmark)Nordic Bioscience (Denmark)Lund University

About

Ulrik Mouritzen is an author at Zealand Pharma (Denmark) specializing in medicine, orthopaedics, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	425
2	Cell Biology	1	1	34
3	Cellular Physiology	1	1	34
4	Diabetes	1	1	21
5	Endocrinology	1	1	131

Ulrik Mouritzen

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index Ulrik Mouritzen Annals of the Rheumatic Diseases	2003	170
Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial Ian D. Davis, Ben Brady, Richard Kefford, Clinical Cancer Research	2009	138
Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM) Stephan Christgau, László B. Tankó, Paul A. Cloos, Menopause The Journal of The North American Menopause Society GynecologyMenopausal Hormone TherapyMenstrual CycleOsteoporosisCartilage Turnover	2004	131
Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women Laacuteszloacute B. Tankoacute, Lusine Movsesyan, Ulrik Mouritzen, Metabolism ObesityBody CompositionSurgerySarcopenic ObesityHealthy Women	2002	121
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog Ulrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen, Diabetes Care	2017	108
Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial Rahim M. Naimi, Mark Hvistendahl, Lotte Hahn Enevoldsen, The Lancet. Gastroenterology & hepatology Functional Gastrointestinal DisorderShort Bowel SyndromeMedicineRandomised Phase 2Gastroenterology	2019	75
Biphasic Insulin Aspart Given Thrice Daily is as Efficacious as a Basal-Bolus Insulin Regimen with Four Daily Injections Robert J. Ligthelm, Ulrik Mouritzen, Helle Lynggaard, Experimental and Clinical Endocrinology & Diabetes	2006	68
Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial Henrik Schmidt, Janet Brown, Ulrik Mouritzen, Clinical Cancer Research	2010	56
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens László B. Tankó, Ulrik Mouritzen, Hans-Jørgen Lehmann, Bone Bone DiseaseBone HealthWeekly TherapyOral IbandronateOsteoarthritis	2003	43
Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial Stanislav Ignatenko, Birte K. Skrumsager, Ulrik Mouritzen International Journal of Clinical Pharmacology and Therapeutics	2016	43

Page 1